AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial - Schmid, P; Abraham, J; Chan, S (J Clin Oncol, 2018)
(Suppl.)